Previous 10 | Next 10 |
2024-06-20 08:45:59 ET Palm Beach, FL – June 20, 2024 – Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of pancreatic adenocar...
PALM BEACH, Fla., June 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Pancreatic cancer is among the most frequently diagnosed and the seventh leading cause of cancer death globally. Pancreatic cancer becomes more common in the Western world. The prevalence rate of panc...
2024-06-20 08:15:00 ET Amgen (NASDAQ: AMGN) is a top drugmaker whose shares have risen by more than 70% in five years, which is a bit shy of the S&P 500 's 90% gain over that stretch. With some promising products in its pipeline, the future does looks encouraging. However, s...
2024-06-18 11:23:25 ET Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and h...
2024-06-17 11:30:03 ET Summary Amgen continues to delight investors with the growth in sales of its key blockbusters and the expansion of its portfolio of medications. In mid-June, Amgen pleased investors by announcing that the FDA had approved Blincyto to treat certain patients w...
2024-06-17 10:09:54 ET The Dow Jones Industrial Average (DJIA) is a widely recognized stock market index that represents 30 large, publicly-owned companies based in the United States. These companies are leaders across diverse sectors, making the Dow a general indicator of the market...
2024-06-16 07:19:35 ET Summary Sanofi's shares have not fully recovered since announcing a business strategy change in October 2023, focusing on R&D investments and on separating its consumer healthcare business unit. The company's immunology business, led by Dupixent and othe...
2024-06-14 17:13:58 ET More on Amgen Amgen Inc. (AMGN) Goldman Sachs 45th Annual Global Healthcare Conference Transcript Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card Amgen Stock: Poised To Break Out (Technical Analysis) Amgen posts ...
FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE PR Newswire BLINCYTO ® Added to Multiphase Consolidation Chemotherapy Reduced Risk of Deat...
2024-06-14 10:24:55 ET Summary Structure Therapeutics Inc. shares surged over 50% on positive GSBR-1290 data, competing with other oral GLP-1R clinical rivals. However, GSBR-1290's efficacy at week 12 fell below Novo Nordisk's amycretin, but still competitive in the obesity treatm...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 07:58:00 ET Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash payments. Just as importantly, Amgen is a recent revenue growe...
2024-07-14 06:30:00 ET Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive dividend yields . Three Motley Fool contributors think they've ...
2024-07-12 12:30:05 ET UBS analyst issues NEUTRAL recommendation for AMGN on July 12, 2024 10:22AM ET. The previous analyst recommendation was Neutral. AMGN was trading at $331.355 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...